FI82266C
(fi)
*
|
1982-10-19 |
1991-02-11 |
Cetus Corp |
Foerfarande foer framstaellning av il-2 -mutein.
|
DK265384A
(da)
*
|
1983-06-01 |
1984-12-02 |
Hoffmann La Roche |
Polypeptider med interferonaktivitet
|
WO1985000817A1
(en)
*
|
1983-08-10 |
1985-02-28 |
Amgen |
Microbial expression of interleukin ii
|
GB8334102D0
(en)
*
|
1983-12-21 |
1984-02-01 |
Searle & Co |
Interferons with cysteine pattern
|
WO1985004328A1
(en)
|
1984-03-28 |
1985-10-10 |
Cetus Corporation |
Pharmaceutical compositions of microbially produced interleukin-2
|
US4530787A
(en)
*
|
1984-03-28 |
1985-07-23 |
Cetus Corporation |
Controlled oxidation of microbially produced cysteine-containing proteins
|
ATE48641T1
(de)
*
|
1984-05-08 |
1989-12-15 |
Genetics Inst |
Ein menschlicher t-zellwachstumsfaktor.
|
GB8412564D0
(en)
*
|
1984-05-17 |
1984-06-20 |
Searle & Co |
Structure and properties
|
IL75318A
(en)
*
|
1984-05-31 |
1994-08-26 |
Genentech Inc |
Recombinant human memotoxin and methods for its recombinant production
|
US5683688A
(en)
*
|
1984-05-31 |
1997-11-04 |
Genentech, Inc. |
Unglycosylated recombinant human lymphotoxin polypeptides and compositions
|
US5672347A
(en)
*
|
1984-07-05 |
1997-09-30 |
Genentech, Inc. |
Tumor necrosis factor antagonists and their use
|
CA1275954C
(en)
|
1984-08-31 |
1990-11-06 |
Hing Cheug Wong |
3'-expression enhancing fragments and method
|
WO1986002068A1
(en)
*
|
1984-09-26 |
1986-04-10 |
Takeda Chemical Industries, Ltd. |
Mutual separation of proteins
|
IL76360A0
(en)
|
1984-09-26 |
1986-01-31 |
Takeda Chemical Industries Ltd |
Mutual separation of proteins
|
US4606917A
(en)
*
|
1984-10-03 |
1986-08-19 |
Syntex (U.S.A) Inc. |
Synergistic antiviral composition
|
US4857316A
(en)
*
|
1984-10-03 |
1989-08-15 |
Syntex (U.S.A.) Inc. |
Synergistic antiviral composition
|
US4959314A
(en)
|
1984-11-09 |
1990-09-25 |
Cetus Corporation |
Cysteine-depleted muteins of biologically active proteins
|
US4572798A
(en)
*
|
1984-12-06 |
1986-02-25 |
Cetus Corporation |
Method for promoting disulfide bond formation in recombinant proteins
|
US5342614A
(en)
*
|
1984-12-21 |
1994-08-30 |
Otsuka Pharmaceutical Co., Ltd. |
Method of treating arthritus or inflammation with IL-1β or derivatives thereof
|
DK172052B1
(da)
*
|
1984-12-21 |
1997-09-29 |
Otsuka Pharma Co Ltd |
Antitumor-aktivt stof, fremgangsmåde til dets fremstilling, lægemiddel indeholdende stoffet, gen kodende for stoffet, vektor indeholdende genet samt rekombinant mikroorganisme transformet med en sådan vektor
|
US6107465A
(en)
*
|
1984-12-21 |
2000-08-22 |
Otsuka Pharmaceutical Co., Ltd. |
IL-1β and derivatives thereof and drugs
|
DE3500681A1
(de)
*
|
1985-01-11 |
1986-07-17 |
Hoechst Ag, 6230 Frankfurt |
Verfahren zur isolierung und reinigung von lymphokinen
|
US4863849A
(en)
*
|
1985-07-18 |
1989-09-05 |
New York Medical College |
Automatable process for sequencing nucleotide
|
US4810643A
(en)
*
|
1985-08-23 |
1989-03-07 |
Kirin- Amgen Inc. |
Production of pluripotent granulocyte colony-stimulating factor
|
US6004548A
(en)
|
1985-08-23 |
1999-12-21 |
Amgen, Inc. |
Analogs of pluripotent granulocyte colony-stimulating factor
|
CA1297003C
(en)
*
|
1985-09-20 |
1992-03-10 |
Jack H. Nunberg |
Composition and method for treating animals
|
US5359035A
(en)
*
|
1985-12-21 |
1994-10-25 |
Hoechst Aktiengesellschaft |
Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
|
AU595864B2
(en)
*
|
1986-03-14 |
1990-04-12 |
Otsuka Pharmaceutical Co., Ltd. |
Il-1 alpha derivatives and drugs
|
US5008374A
(en)
*
|
1986-03-14 |
1991-04-16 |
Otsuka Pharmaceutical Co., Ltd. |
IL-1α derivatives and drugs
|
DE3683910D1
(de)
*
|
1986-09-05 |
1992-03-26 |
Cetus Corp |
Oxidationsresistente muteine von beta-interferon, deren herstellung und diese muteine enthaltende praeparate.
|
JP2526965B2
(ja)
*
|
1987-02-24 |
1996-08-21 |
武田薬品工業株式会社 |
ムテイン,dnaおよびその用途
|
US4987070A
(en)
*
|
1987-03-04 |
1991-01-22 |
Suntory Limited |
Use of a 97 amino acid leader sequence from the E. coli B-galactosidase gene for the production of hanp and hptc as fusion proteins
|
AU629176B2
(en)
*
|
1987-07-07 |
1992-10-01 |
Scios Nova Inc. |
Recombinant fibroblast growth factors
|
ATE163013T1
(de)
*
|
1987-11-04 |
1998-02-15 |
Byk Gulden Lomberg Chem Fab |
Alveolare oberflächenaktive proteine
|
EP0355460B1
(en)
*
|
1988-08-24 |
2000-12-27 |
American Cyanamid Company |
Stabilization of somatotropins by modification of cysteine residues utilizing site directed mutagenesis or chemical derivatization
|
US5079230A
(en)
*
|
1988-09-12 |
1992-01-07 |
Pitman-Moore, Inc. |
Stable bioactive somatotropins
|
CA2003886A1
(en)
*
|
1988-12-16 |
1990-06-16 |
Anthony F. Purchio |
Cloning and expression of simian transforming growth factor-beta 1
|
AU620673B2
(en)
*
|
1989-01-31 |
1992-02-20 |
Pharmacia & Upjohn Company |
Somatotropin analogs
|
EP0383599B1
(en)
*
|
1989-02-17 |
1996-02-07 |
Merck & Co. Inc. |
Protein anti-cancer agent
|
US5621078A
(en)
*
|
1989-03-22 |
1997-04-15 |
Merck & Co., Inc. |
Modified pseudomonas exotoxin PE40
|
WO1990012877A1
(en)
*
|
1989-04-19 |
1990-11-01 |
Cetus Corporation |
Multifunctional m-csf proteins and genes encoding therefor
|
US6207798B1
(en)
|
1989-08-03 |
2001-03-27 |
Merck & Co., Inc. |
Modified PE40 toxin fusion proteins
|
US5173297A
(en)
*
|
1991-07-01 |
1992-12-22 |
Quest International Flavors & Food Ingredients Company Division Of Indopco, Inc. |
Bacteriocin from lactococcus lactis subspecies lactis
|
IL98528A0
(en)
*
|
1990-06-21 |
1992-07-15 |
Merck & Co Inc |
Pharmaceutical compositions containing hybrid for killing bladder cancer cells
|
FR2671554A1
(fr)
*
|
1991-01-11 |
1992-07-17 |
Clonatec Sa |
Peptides synthetiques derivant de l'antigene hbc du virus de l'hepatite b, leurs applications a la detection d'une infection par ce virus et a la vaccination contre l'hepatite b.
|
US5545723A
(en)
*
|
1994-03-15 |
1996-08-13 |
Biogen Inc. |
Muteins of IFN-β
|
US5814485A
(en)
*
|
1995-06-06 |
1998-09-29 |
Chiron Corporation |
Production of interferon-β (IFN-β) in E. coli
|
DE19544167A1
(de)
*
|
1995-11-17 |
1997-05-22 |
Schering Ag |
Verwendung von Interferon-ß zur Behandlung von Bronchialkarzinom bei Bestrahlungstherapie
|
WO1997048808A1
(en)
*
|
1996-06-19 |
1997-12-24 |
Chiron Corporation |
Bacterial production of interferon-beta using low levels of sodium and potassium ions
|
CN1100875C
(zh)
*
|
1998-03-06 |
2003-02-05 |
上海华晨生物技术研究所 |
新型重组人白细胞介素2的制备方法及其表达载体和工程菌
|
JP2003531590A
(ja)
|
2000-04-12 |
2003-10-28 |
ヒューマン ゲノム サイエンシズ インコーポレイテッド |
アルブミン融合タンパク質
|
EP1935431A3
(en)
|
2000-05-15 |
2008-08-13 |
Health Research, Inc. |
Cancer treatments by using a combination of an antibody against her2 and interleukin-2
|
DE10112825A1
(de)
|
2001-03-16 |
2002-10-02 |
Fresenius Kabi De Gmbh |
HESylierung von Wirkstoffen in wässriger Lösung
|
US6887462B2
(en)
|
2001-04-09 |
2005-05-03 |
Chiron Corporation |
HSA-free formulations of interferon-beta
|
EP1435979A4
(en)
*
|
2001-09-18 |
2008-01-23 |
Novartis Vaccines & Diagnostic |
METHODS OF TREATING MULTIPLE SCLEROSIS
|
KR100511749B1
(ko)
*
|
2001-11-06 |
2005-09-02 |
선바이오(주) |
변형된 인터페론-베타, 및 이의 화학적으로 변형된 배합체
|
EP1997829A1
(en)
|
2001-12-21 |
2008-12-03 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
DE10209822A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
|
DE10209821A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung von Proteinen an ein modifiziertes Polysaccharid
|
BR0314106A
(pt)
|
2002-09-11 |
2005-07-19 |
Fresenius Kabi De Gmbh |
Polipeptìdeos hasilados, especialmente eritropoietina hasilada
|
AU2003273413A1
(en)
|
2002-10-08 |
2004-05-04 |
Fresenius Kabi Deutschland Gmbh |
Pharmaceutically active oligosaccharide conjugates
|
WO2005014655A2
(en)
|
2003-08-08 |
2005-02-17 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein
|
JP4746552B2
(ja)
|
2003-11-04 |
2011-08-10 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
自己免疫疾患および炎症性疾患ならびに臓器移植拒絶の処置のためのアンタゴニスト抗cd40抗体の使用
|
EP1723251A4
(en)
*
|
2004-03-05 |
2008-04-23 |
Novartis Vaccines & Diagnostic |
IN VITRO TESTING SYSTEM FOR PREDICTING THE TOLERABILITY OF THERAPEUTIC AGENTS IN PATIENTS
|
JP5191729B2
(ja)
|
2004-03-11 |
2013-05-08 |
フレゼニウス・カビ・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
還元的アミノ化によって製造される、ヒドロキシアルキルデンプンとタンパク質とのコンジュゲート
|
JP2008507297A
(ja)
*
|
2004-07-26 |
2008-03-13 |
エンゾン ファーマシューティカルズ,インコーポレーテッド |
最適化されたインターフェロンβ遺伝子
|
GB0523282D0
(en)
|
2005-11-15 |
2005-12-21 |
Isis Innovation |
Methods using pores
|
GB2453377A
(en)
|
2007-10-05 |
2009-04-08 |
Isis Innovation |
Transmembrane protein pores and molecular adapters therefore.
|
EP2070950A1
(en)
|
2007-12-14 |
2009-06-17 |
Fresenius Kabi Deutschland GmbH |
Hydroxyalkyl starch derivatives and process for their preparation
|
EP2085095B1
(en)
|
2008-01-17 |
2012-03-07 |
Philogen S.p.A. |
Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart
|
WO2010004265A1
(en)
|
2008-07-07 |
2010-01-14 |
Oxford Nanopore Technologies Limited |
Enzyme-pore constructs
|
JP2011527191A
(ja)
|
2008-07-07 |
2011-10-27 |
オックスフォード ナノポア テクノロジーズ リミテッド |
塩基検出細孔
|
US9077937B2
(en)
*
|
2008-11-06 |
2015-07-07 |
Alcatel Lucent |
Method and apparatus for fast channel change
|
GB0820927D0
(en)
|
2008-11-14 |
2008-12-24 |
Isis Innovation |
Method
|
JP5843614B2
(ja)
|
2009-01-30 |
2016-01-13 |
オックスフォード ナノポア テクノロジーズ リミテッド |
膜貫通配列決定における核酸構築物のためのアダプター
|
CN102482330A
(zh)
|
2009-01-30 |
2012-05-30 |
牛津纳米孔技术有限公司 |
酶突变体
|
GB0905140D0
(en)
|
2009-03-25 |
2009-05-06 |
Isis Innovation |
Method
|
CA2826374C
(en)
|
2011-02-11 |
2024-01-23 |
Oxford Nanopore Technologies Limited |
Mutant pores
|
MX347324B
(es)
|
2011-03-11 |
2017-04-19 |
Assist Publique-Hôpitaux De Paris |
Uso de dosis bajas de il-2 para tratar trastornos inflamatorios o relacionados con la autoinmunidad.
|
WO2013014451A1
(en)
|
2011-07-25 |
2013-01-31 |
Oxford Nanopore Technologies Limited |
Hairpin loop method for double strand polynucleotide sequencing using transmembrane pores
|
GB201119244D0
(en)
|
2011-11-08 |
2011-12-21 |
British American Tobacco Co |
Smoking article
|
WO2013153359A1
(en)
|
2012-04-10 |
2013-10-17 |
Oxford Nanopore Technologies Limited |
Mutant lysenin pores
|
US11155860B2
(en)
|
2012-07-19 |
2021-10-26 |
Oxford Nanopore Technologies Ltd. |
SSB method
|
US10221450B2
(en)
|
2013-03-08 |
2019-03-05 |
Oxford Nanopore Technologies Ltd. |
Enzyme stalling method
|
GB201314695D0
(en)
|
2013-08-16 |
2013-10-02 |
Oxford Nanopore Tech Ltd |
Method
|
GB201313477D0
(en)
|
2013-07-29 |
2013-09-11 |
Univ Leuven Kath |
Nanopore biosensors for detection of proteins and nucleic acids
|
US10183061B2
(en)
|
2013-06-25 |
2019-01-22 |
Icm (Institut Du Cerveau Et De La Moelle Epiniere) |
Boosting Treg cells for treating Alzheimer disease and related disorders
|
GB201403096D0
(en)
|
2014-02-21 |
2014-04-09 |
Oxford Nanopore Tech Ltd |
Sample preparation method
|
EP2918285A1
(en)
|
2014-03-11 |
2015-09-16 |
Université Pierre et Marie Curie (Paris 6) |
Interleukin-2 for treating food allergy
|
WO2015166276A1
(en)
|
2014-05-02 |
2015-11-05 |
Oxford Nanopore Technologies Limited |
Method of improving the movement of a target polynucleotide with respect to a transmembrane pore
|
CN117164684A
(zh)
|
2014-09-01 |
2023-12-05 |
弗拉芒区生物技术研究所 |
突变csgg孔
|
US10266885B2
(en)
|
2014-10-07 |
2019-04-23 |
Oxford Nanopore Technologies Ltd. |
Mutant pores
|
GB201418159D0
(en)
|
2014-10-14 |
2014-11-26 |
Oxford Nanopore Tech Ltd |
Method
|
US10801023B2
(en)
*
|
2015-04-24 |
2020-10-13 |
University Of Florida Research Foundation, Inc. |
Methods of identifying biologically active random peptides in plants and libraries of plants expressing candidate biologically active random peptides
|
WO2016172445A2
(en)
*
|
2015-04-24 |
2016-10-27 |
The University Of Florida Research Foundation, Inc. |
Methods of identifying biologically active random peptides in plants and libraries of plants expressing candidate biologically active random peptides
|
US10876109B2
(en)
|
2015-04-24 |
2020-12-29 |
University Of Florida Research Foundation, Inc. |
Methods of identifying biologically active random peptides in prokaryotic cells and libraries of prokaryotic cells expressing candidate biologically active random peptides
|
MX2018004883A
(es)
|
2015-10-22 |
2018-08-01 |
Iltoo Pharma |
Composiciones farmaceuticas de il-2.
|
GB201609220D0
(en)
|
2016-05-25 |
2016-07-06 |
Oxford Nanopore Tech Ltd |
Method
|
US11648271B2
(en)
|
2016-06-22 |
2023-05-16 |
David Klatzmann |
Genetically modified T lymphocytes
|
EP3596108A4
(en)
|
2017-03-15 |
2020-12-23 |
Pandion Operations, Inc. |
TARGETED IMMUNOTOLERANCE
|
US10676516B2
(en)
|
2017-05-24 |
2020-06-09 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
US11534479B2
(en)
|
2018-02-16 |
2022-12-27 |
Iltoo Pharma |
Use of interleukin 2 for treating Sjögren's syndrome
|
GB201807793D0
(en)
|
2018-05-14 |
2018-06-27 |
Oxford Nanopore Tech Ltd |
Method
|
EP3806888B1
(en)
|
2018-06-12 |
2024-01-31 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
WO2020007937A1
(en)
|
2018-07-03 |
2020-01-09 |
Iltoo Pharma |
Use of interleukin-2 for treating systemic sclerosis
|
EP3836954A1
(en)
|
2018-08-13 |
2021-06-23 |
Iltoo Pharma |
Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
|
EP3880838A4
(en)
|
2018-11-15 |
2022-11-02 |
The Board of Trustees of the Leland Stanford Junior University |
COMPOSITIONS AND METHODS FOR PRODICTING AND CLASSIFICATION OF PREECLAMPIA
|
AU2020279240A1
(en)
|
2019-05-20 |
2021-12-23 |
Pandion Operations, Inc. |
MAdCAM targeted immunotolerance
|
IL293628A
(en)
|
2019-12-12 |
2022-08-01 |
Iltoo Pharma |
Interleukin 2 chimeric structures
|
US11981715B2
(en)
|
2020-02-21 |
2024-05-14 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a CD39 effector
|
WO2021176044A1
(en)
|
2020-03-06 |
2021-09-10 |
Centre Hospitalier Universitaire De Nimes |
Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis
|
BR112022022035A2
(pt)
*
|
2020-04-29 |
2023-01-03 |
Abion Inc |
Interferon-beta humano variante, polinucleotídeo, vetor de expressão, célula animal transformada, métodos para preparar um interferon-beta humano variante, melhorar a estabilidade de um interferon-beta r27t humano variante e tratar uma doença, composição farmacêutica e uso
|
JP2023528582A
(ja)
*
|
2020-04-29 |
2023-07-05 |
ジェノファーム インク. |
インターフェロンβ変異体と抗体が融合された組換えタンパク質およびそれを含む薬学的組成物
|
AU2022360645A1
(en)
|
2021-10-06 |
2024-05-02 |
Assistance Publique - Hôpitaux De Paris |
Interleukin 2 chimeric constructs with targeting specificity to inflamed tissues
|
WO2024056154A1
(en)
|
2022-09-12 |
2024-03-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Interleukin-2 for use in treating autism spectrum disorder
|
WO2024121173A1
(en)
|
2022-12-05 |
2024-06-13 |
Centre Hospitalier Universitaire De Nimes |
Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis in a subgroup of patients
|